Mirabegron is a selective β3 adrenergic receptor agonist primarily used to treat symptoms caused by overactive bladder (OAB). This medication works by selectively stimulating β3 receptors on the bladder smooth muscle, relaxing the overactive detrusor muscle, and improving symptoms such as urgency incontinence, frequency, and urinary urgency. Unlike traditional anticholinergic drugs, Mirabegron acts directly on the bladder muscle, offering an alternative treatment option.
Clinical trials have shown that this drug can significantly reduce the number of voids per day and prolong the interval between urinations. Its mechanism of action is unique, with minimal effects on β receptors outside the bladder (such as β1 and β2 receptors in the heart), resulting in fewer cardiovascular side effects.
The generic name of this drug is Mirabegron, with the main brand name being Myrbetriq. Different countries may have other trade names, but the generic drug has been marketed in most regions. Patients should verify that the active ingredient on the medication packaging is Mirabegron and follow their physician’s prescription.
Mirabegron is classified as a selective β3 adrenergic receptor agonist, representing an emerging class of drugs for overactive bladder treatment. This class differs from anticholinergic drugs (such as Solifenacin), targeting neural regulation of the bladder muscle and providing a multifaceted treatment approach.
This medication is approved for adult patients experiencing symptoms of overactive bladder, including:
It is suitable for patients with acute and neurogenic overactive bladder, but should be used in conjunction with a healthcare provider’s assessment of other potential causes.
Mild side effects include:
Serious side effects are rare but require attention:
Contraindications:
The pregnancy category is C; women who are pregnant or planning pregnancy should weigh risks and benefits. Use during breastfeeding may lead to secretion into breast milk; caution is advised. Dose adjustments are necessary for patients with hepatic or renal impairment.
Concomitant use with CYP2D6 inhibitors (such as Paroxetine, Fluoxetine) may increase blood concentrations, requiring dose adjustments. Avoid combining with strong CYP2D6 inducers (such as Carbamazepine), which may reduce efficacy.
Using with other antihypertensive agents (such as norepinephrine) may enhance blood pressure lowering effects. Patients should inform their healthcare provider of all prescription medications, over-the-counter drugs, and herbal supplements they are taking.
The usual starting dose is 50mg once daily, which can be adjusted to 100mg based on efficacy and tolerability. The medication should be swallowed whole and can be taken with or without food, but taking it at a fixed time daily is recommended to maintain stable drug levels.
Patients with severe hepatic impairment (Child-Pugh C) should reduce the dose to 50mg once daily. Dose adjustments are also necessary for patients with renal impairment based on creatinine clearance to prevent accumulation and toxicity.
If a dose is missed and more than 6 hours remain before the next scheduled dose, take it as soon as possible. If it is close to the next dose time, skip the missed dose and resume the regular schedule. Do not double doses to make up for missed ones.
Overdose may cause palpitations, dizziness, hypertension, or decreased urine output. Immediate medical attention is required if symptoms occur. Treatment may include administration of β-blockers or hemodialysis, but non-selective β-blockers should be avoided.
Mirabegron can be taken with or without food, and its administration is not affected by meals. To reduce gastrointestinal discomfort, it is recommended to take the medication at a consistent time and maintain regular eating habits. Avoid excessive alcohol intake, as it may enhance the drug’s effect on blood pressure.
How to manage potential side effects such as dry mouth or constipation during long-term use of Mirabegron?Dry mouth can be alleviated by increasing fluid intake or using sugar-free lozenges; constipation can be managed by increasing dietary fiber, maintaining regular exercise, and, if severe, consulting a healthcare provider for dose adjustment or laxative use. Persistent or worsening symptoms should prompt medical evaluation.
What drug interactions should be considered when combining Mirabegron with other antihypertensive medications?Combining Mirabegron with diuretics or β-blockers may enhance blood pressure lowering effects, potentially causing orthostatic hypotension. Healthcare providers will adjust doses based on blood pressure monitoring. Patients should regularly monitor their blood pressure and avoid sudden standing or prolonged standing.
Do I need to limit fluid intake or adjust urination habits while using Mirabegron?There is no need to deliberately restrict water intake, but avoiding large volumes of water in a short period can help reduce the sensation of frequent urination. Urination habits should follow natural needs. If difficulty urinating or urinary retention occurs, the medication should be discontinued immediately and medical attention sought, as these may be contraindications.
Is gradual dose reduction necessary when discontinuing Mirabegron to prevent withdrawal reactions?There is no clear evidence that gradual tapering is required, but discontinuation should be determined by a healthcare provider. If symptoms worsen after sudden cessation (such as bladder discomfort or urinary retention), follow-up with a healthcare provider is recommended to adjust the treatment plan and avoid self-modification of medication.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
